| Name | Pirinixic Acid |
| Description | Pirinixic Acid (NSC 310038) is a synthetic thiacetic acid derivative used in biomedical research, carcinogenic Pirinixic acid is a peroxisome proliferator that activates specific peroxisome proliferator-activated receptors (PPAR). |
| Kinase Assay | Fluorescence Polarization Assay: Binding of HSP90 inhibitors to human full-length recombinant HSP90β is determined by a competitive binding fluorescence polarization assay, using a fluorescent pyrazole resorcinol probe. |
| In vitro | WY14643 significantly reduced visceral fat mass and total liver triglyceride content without increasing body weight. It enhanced systemic insulin sensitivity and improved insulin-mediated skeletal muscle glucose metabolism in both red (47%) and white (63%) muscle fibers, as well as in white adipose tissue (90%), while reducing muscle triglyceride and LCACoA accumulation. Administration of WY14643 (1 mg/kg i.v.) 30 minutes before left anterior descending artery occlusion led to a notable reduction in infarct size (~44%) in rats subjected to myocardial ischemia (25 minutes) followed by reperfusion (2 hours). In rats fed a high-fat diet, treatment with 3 mg/kg WY14643 lowered plasma glucose and triglyceride levels (-16% vs. untreated), leptin (-52%), muscle triglycerides (-34%), and overall long-chain acyl-coenzyme A (-41%) levels. |
| In vivo | WY14643 (250 μM) significantly reduces the expression levels of VCAM-1, lowering it to 52% of those in human endothelial cells stimulated by TNF-α. At a concentration of 10 μM, WY 14643 acts on aortic smooth muscle cells to almost completely inhibit the production of IL-6 and prostaglandin induced by IL-1, as well as the expression of cyclooxygenase-2, through the suppression of the NF-κB signaling pathway. Pre-treating endothelial cells with WY 14643 (10 μM) before TNF-α stimulation decreases U937 cell adhesion by 50%. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 255 mg/mL (787.52 mM), Sonication is recommended.
|
| Keywords | Wy14643 | Wy 14643 | PPARα | PPAR | Pirinixic Acid | Peroxisome proliferator-activated receptors | NSC-310038 | NSC310038 | Inhibitor | inhibit |
| Inhibitors Related | PHYTOL | Rosiglitazone | Retinoic acid | Daidzein | Fenofibrate | Magnesium acetate tetrahydrate | Maltitol | Naringenin | 2,3-Butanediol | NPC 15199 | Icariin | Cloxiquine |
| Related Compound Libraries | Nuclear Receptor Compound Library | Ferroptosis Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Anti-Diabetic Compound Library | Anti-Breast Cancer Compound Library | NO PAINS Compound Library | Anti-Cardiovascular Disease Compound Library | Lipid Metabolism Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
